{"id":"docetaxel-capecitabine-cisplatin-bevacizumab","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Headache"},{"rate":"5-20%","effect":"Dizziness"},{"rate":"5-20%","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Docetaxel works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division. Capecitabine is converted into 5-fluorouracil, which inhibits thymidylate synthase and interferes with DNA synthesis. Cisplatin forms platinum-DNA adducts that prevent DNA replication and transcription. Bevacizumab binds to vascular endothelial growth factor and prevents its interaction with its receptor, thereby inhibiting angiogenesis.","oneSentence":"Docetaxel is a microtubule inhibitor that disrupts cell division, Capecitabine is a thymidylate synthase inhibitor that interferes with DNA synthesis, Cisplatin is a platinum-based alkylating agent that cross-links DNA, Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:33:51.418Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer, Metastatic non-small cell lung cancer, Metastatic gastric cancer, Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT01471470","phase":"PHASE2","title":"Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2010-07","conditions":"Advanced Gastric Cancer","enrollment":31},{"nctId":"NCT00737438","phase":"PHASE2","title":"Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-08","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":22},{"nctId":"NCT00845884","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2009-02","conditions":"Advanced Gastric Cancer","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Docetaxel, Capecitabine, Cisplatin, Bevacizumab","genericName":"Docetaxel, Capecitabine, Cisplatin, Bevacizumab","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel is a microtubule inhibitor that disrupts cell division, Capecitabine is a thymidylate synthase inhibitor that interferes with DNA synthesis, Cisplatin is a platinum-based alkylating agent that cross-links DNA, Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor. Used for Metastatic breast cancer, Metastatic non-small cell lung cancer, Metastatic gastric cancer, Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}